Comparative Pharmacology
Head-to-head clinical analysis: AQUATENSEN versus UNIRETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUATENSEN versus UNIRETIC.
AQUATENSEN vs UNIRETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQUATENSEN (methylclothiazide) is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and blood pressure.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
1-2 mg orally once daily, titrated to blood pressure response; maximum dose 4 mg/day.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours (mean 10 h); clinically, allows twice-daily dosing
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Renal: 50% unchanged; Fecal: 20% (via bile); remainder as inactive metabolites
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Category C
Category C
Diuretic
ACE Inhibitor and Diuretic